agena-bioscience-logo
  • Technology
  • Applications
  • Resources
  • Support
  • Company
  • Contact
EN - Global CN - 中国

menu

agena-bioscience-logo agena-bioscience-logo Close
  • Home
  • Technology
  • Applications
    • Pharmacogenetics
    • Liquid Biopsy
    • Mutation Profiling
    • Hereditary Genetics
    • Methylation
    • Sample Integrity
    • Specimen Validity
  • Services
    • Assays by Agena
    • Certified Service Providers
  • Resources
    • Product Literature
    • Publication Library
  • Support
    • Service Plans
    • Distributors
    • Certified Service Providers
  • Company
    • Careers
    • Press
  • Contact
  • Customer Support Portal
  • Home
  • Technology
  • Applications
    • Pharmacogenetics
    • Mutation Profiling
    • Liquid Biopsy
    • Hereditary Genetics
    • Methylation
    • Sample Integrity
    • Specimen Validity
  • Services
    • Assays by Agena
    • Certified Service Providers
  • Resources
    • Product Literature
    • Publication Library
  • Support
    • Service Plans
    • Distributors
    • Certified Service Providers
  • Company
    • Careers
    • Press
  • Contact
  • Customer Support Portal

Phone: (858) 882-2800

Home / Resources / Publication Library / Publication Library Search

Publication Library

Search All publications

  • PURPOSE: A previous study noted frequent B-RAF mutations among European patients with cisplatin-resistant but not cisplatin-sensitive germ cell tumors (GCT). We sought to validate this finding by assessing for these mutations among GCT patients at our center. Patients and Methods: Adolescent and adult patients with GCT who received cisplatin-based chemotherapy and had tumor tissue available were eligible for participation. Response to cisplatin was reviewed to determine sensitivity and resistance. Tumor DNA was extracted and subjected to Sequenom analysis to detect hotspot alterations in FGFR3, AKT1, PIK3CA, KRAS, HRAS, NRAS, and BRAF with Sanger Sequencing for confirmation. Nine GCT cell lines with varying degrees of cisplatin sensitivity and resistance were also assayed by Sequenom. RESULTS: Seventy (24 cisplatin-sensitive; 46 cisplatin-resistant) of 75 patients had tumors with sufficient quality DNA to perform Sequenom. Nineteen mutations were detected among 16 (23%) patients but no BRAF mutations were identified. Similarly, none of the cell lines harbored BRAF mutations. FGFR3 was the most frequent mutation, identified in 13% of both sensitive and resistant samples. All other mutations were exclusive to resistant cases (3 KRAS, 3 AKT1, 3 PIK3CA, 1 HRAS). CONCLUSIONS: BRAF mutations are rare in American GCT patients, including those with cisplatin-resistance. However, other potentially targetable mutations occur in over 25% of cisplatin-resistant patients. FGFR3, AKT1 and PIK3CA mutations are all reported for the first time in GCT. Whereas FGFR3 mutations occurred with equal frequency in both sensitive and resistant GCT, mutations in AKT1 and PIK3CA were observed exclusively in cisplatin-resistant tumors.
  • Association of polymorphisms in the vascular endothelial growth factor gene and its serum levels with diabetic retinopathy in Chinese patients with type 2 diabetes: A cross-sectional study
  • Association of polymorphisms of the xeroderma pigmentosum complementation group F gene with increased glioma risk
  • Association of Promoter Methylation Statuses of Congenital Heart Defect Candidate genes with Tetralogy of Fallot
  • Association of SNPs of DYX1C1 with developmental dyslexia in an Indian population
  • Association of the Hepatocyte Growth Factor Gene with Keratoconus in an Australian Population
  • ALK Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescent In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment
  • Association of c(-106)t polymorphism in aldose reductase gene with diabetic retinopathy in Chinese patients with type 2 diabetes mellitus
  • Amerindian-specific regions under positive selection harbour new lipid variants in Latinos
  • Polymorphisms in methylenetetrahydrofolate reductase gene and risk of non-Hodgkin lymphoma in a multi-ethnic population
«...102030...742743744745746...750760770...»
Products
  • Technology
  • Applications
  • Custom Assays
Resources
  • Product Literature
  • Publication Library
  • ISO Certifications
  • Patents
    Support
    • Support Contacts
    • Service Plans
    • Certified Service Providers
    • Distributors
    • Customer Support Portal
Company
  • About Us
  • Careers
  • Contact
footer-logo
Agena Bioscience

4755 Eastgate Mall,
San Diego, CA 92121

(877) 443-6663

With exception of the MassARRAY Dx, all other products are For Research Use Only. Not for use in diagnostic procedures.
© 2020-2025 Agena Bioscience, Inc. All rights reserved. Agena Bioscience is a subsidiary of Mesa Labs, Inc.

  • footer-mesalabs-logo
  • footer-protein-logo
  • footer-gke-logo
  • Privacy Policy
  • Website Terms & Conditions
  • Product Terms & Conditions
  • Warranty